Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Designing multi-arm multistage adaptive trials for neuroprotection in progressive multiple slerosis

Tools
- Tools
+ Tools

Li, Vivien, Leurent, Baptiste, Barkhof, Frederik, Braisher, Marie, Cafferty, Fay H., Ciccarelli, Olga, Eshaghi, Arman, Gray, Emma, Nicholas, Jennifer M., Parmar, Mahesh K. B., Peryer, Guy, Robertson, Jenny, Stallard, Nigel, Wason, James and Chataway, Jeremy (2022) Designing multi-arm multistage adaptive trials for neuroprotection in progressive multiple slerosis. Neurology, 98 (18). pp. 754-764. doi:10.1212/WNL.0000000000200604

[img]
Preview
PDF
WRAP-designing-multi-arm-multistage-adaptive-trials-neuroprotection-progressive-multiple-slerosis-Stallard-2022.pdf - Accepted Version - Requires a PDF viewer.
Available under License Creative Commons Attribution 4.0.

Download (1041Kb) | Preview
Official URL: http://dx.doi.org/10.1212/WNL.0000000000200604

Request Changes to record.

Abstract

Progressive multiple sclerosis (PMS) is a significant health problem with few treatments shown to slow disability progression. One challenge has been efficiently testing the pipeline of candidate therapies from preclinical studies in clinical trials. Multi-arm multi-stage (MAMS) platform trials may accelerate evaluation of new therapies compared to traditional sequential clinical trials. We describe a MAMS design in PMS, focusing on selection of interim and final outcome measures, sample size and statistical considerations.

The UK MS Society Expert Consortium for Progression in MS Clinical Trials reviewed recent phase II and III PMS trials to inform interim and final outcome selection and design parameters. Simulations were performed to evaluate trial operating characteristics under different treatment effect, recruitment rate and sample size assumptions. People with MS formed a Patient and Public Involvement group and contributed to the trial design ensuring it would meet the needs of the MS community.

The proposed design evaluates three experimental arms compared to a common standard of care arm in two stages. Stage 1 (interim) outcome will be whole brain atrophy on MRI at 18 months, assessed for 123 participants per arm. Treatments with sufficient evidence for slowing brain atrophy will continue to the second stage. The stage 2 (final) outcome will be time to six-month confirmed disability progression, based on a composite clinical score comprising the Expanded Disability Status Score, Timed 25-Foot Walk and 9-Hole Peg Test. To detect a hazard ratio of 0.75 for this primary final outcome with 90% power, 600 participants per arm are required. Assuming one treatment progresses to stage 2, the trial will recruit around 1,900 participants and last around 6 years. This is approximately two-thirds the size and half the time of separate two-arm phase II and III trials.

The proposed MAMS trial design will substantially reduce duration and sample size compared to traditional clinical trials, accelerating discovery of effective treatment for PMS. The design was also well-received by people with MS. The practical and statistical principles of MAMS trial design may be applicable to other neurodegenerative conditions to facilitate efficient testing of new therapies.

Item Type: Journal Article
Subjects: R Medicine > RA Public aspects of medicine
R Medicine > RC Internal medicine
Divisions: Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences
Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences > Statistics and Epidemiology
Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH): Multiple sclerosis, Multiple sclerosis -- Treatment, Clinical trials
Journal or Publication Title: Neurology
Publisher: Lippincott Williams & Wilkins
ISSN: 0028-3878
Official Date: May 2022
Dates:
DateEvent
May 2022Published
23 March 2022Available
10 March 2022Accepted
Volume: 98
Number: 18
Page Range: pp. 754-764
DOI: 10.1212/WNL.0000000000200604
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Open Access
RIOXX Funder/Project Grant:
Project/Grant IDRIOXX Funder NameFunder ID
1101Multiple Sclerosis Societyhttp://dx.doi.org/10.13039/501100000381
1110Multiple Sclerosis Societyhttp://dx.doi.org/10.13039/501100000381
PA-1412-02420Multiple Sclerosis International Federationhttp://dx.doi.org/10.13039/501100007459

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics

twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us